Erratum: Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: The OPTIPARK open-label study (Translational Neurodegeneration (2020) 9:9 DOI: 10.1186/s40035-020-00187-1)

Abstract

In this published article [1], the efficacy data for the below outcomes were unfortunately not supplied based on the Full Analysis Set (FAS) at 3 and/or 6 months for specific outcomes under the statistical analysis plan (SAP). The SAP specified that the efficacy data should be based overall on the FAS at 3 months for the primary (with last observation carried forward, LOCF) and secondary (no LOCF) efficacy endpoints and 6months for UK only (no LOCF). The amendments do not change the conclusions of the paper, and the corrected data are given below. (Table Presented).